Phase III KEYNOTE-590 study of chemotherapy plus pembrolizumab versus chemotherapy plus placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer
Yazar
Bhagia, P.
Zhu, Y.
Shah, S.
Doi, T.
Ozguroglu, M.
Kato, K.
Shah, M. A.
Enzinger, P. C.
Bennouna, J.
Shen, L.
Adenis, A.
Sun, J-M.
Cho, B. C.
Kojima, T.
Kostorov, V.
Hierro, C.
Üst veri
Tüm öğe kaydını gösterKoleksiyonlar
- Bildiri [64839]